Amgen Korea announces approval of Blincyto as acute lymphoblastic leukemia treatment
Amgen Korea announced commercialization approval of Blincyto Inj 35μg(generic name: blinatumomab), an acute lymphoblastic leukemia (ALL: Acute Lymphoblastic Leukemia) treatment, as a treatment of Philadelphia chromosome-negative or refractory precursor B-cell acute lymphoblastic leukemia from the...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
